Bellicum pharmaceuticals, inc. (BLCM)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues
Revenues

6,627

7,143

2,322

2,511

1,482

1,120

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants

-

-

-

-

-

-

-

-

-

-

-

-

424

388

341

284

267

282

262

865

1,335

1,780

0

0

0

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

424

388

341

284

267

282

262

865

1,335

1,780

0

0

0

Operating expenses
Research and development

58,135

64,535

71,265

73,347

71,900

71,588

65,669

67,357

66,904

65,663

66,439

61,628

55,700

51,263

46,218

42,720

38,701

33,561

27,712

20,177

15,400

12,071

0

0

0

License fees

-

-

320

459

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License fees

-

-

-

-

-

-

-

-

-

-

-

-

805

580

0

0

0

-

-

-

-

-

-

-

-

General and administrative

26,607

29,972

31,234

28,993

26,842

24,998

23,080

20,691

20,810

21,045

20,202

19,875

18,568

16,925

16,531

16,161

14,759

12,672

10,859

8,277

6,092

4,335

0

0

0

Total operating expenses

84,742

94,507

102,353

102,333

98,712

96,586

89,083

88,394

88,253

87,572

87,790

82,501

75,073

68,768

66,213

62,345

56,774

49,417

81,783

71,666

64,704

59,618

0

0

0

Loss from operations

-78,115

-87,364

-100,031

-99,822

-97,230

-95,466

-88,344

-87,821

-88,042

-87,387

-87,455

-82,178

-74,649

-68,380

-65,872

-62,061

-56,507

-49,135

-81,521

-70,801

-63,369

-57,838

0

0

0

Other income (expense):
Other income (expense):
Interest income

1,295

1,351

1,487

1,656

1,782

1,639

1,463

1,255

1,125

1,055

1,010

950

879

909

896

883

818

641

452

250

82

35

0

0

0

Interest expense

4,195

4,280

4,323

4,309

4,266

4,199

4,078

4,023

3,954

3,672

3,344

2,849

2,359

1,760

1,135

620

134

12

1,753

1,764

1,775

1,791

0

0

0

Change in fair value of warrant and private placement option liabilities

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Other expense

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Total other income (expense)

7,742

-25,113

-10,685

-2,663

-2,494

-2,570

-4,390

-4,543

-4,604

-4,392

-2,344

-1,909

-1,490

-861

-279

221

642

587

-24,477

-25,885

-26,064

-26,127

0

0

0

Net income (loss)

-70,373

-112,477

-110,716

-102,485

-99,724

-98,036

-92,734

-92,364

-92,646

-91,779

-89,799

-84,087

-76,139

-69,241

-66,151

-61,840

-55,865

-48,548

-105,998

-96,686

-89,433

-83,965

0

0

0

Less: undistributed earnings to participating securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,432

0

0

0

Net income (loss) attributable to common shareholders

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-85,397

0

0

0

Net income (loss) per common share attributable to common shareholders, basic (in shares)

1.09

-

-

-

-5.54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per common share attributable to common shareholders, diluted (in shares)

1.09

-

-

-

-5.54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding, basic (in shares)

5,039

-

-

-

4,424

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding, diluted (in shares)

5,040

-

-

-

4,424

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings Per Share, Basic and Diluted

-

-

-0.68

-0.58

-

-22.54

-0.55

-0.60

-0.68

-0.64

-0.71

-0.74

-0.80

-0.74

-0.66

-0.61

-0.56

-0.63

-0.51

-0.40

-0.30

-28.63

-2.08

-1.81

-1.52

Weighted-average shares outstanding-basic and diluted (in shares)

-

-

47,208

46,052

-

-101,304

43,334

40,605

33,456

33,307

33,178

33,074

27,295

27,044

26,966

26,910

26,882

26,481

26,376

26,268

26,259

3,928

2,124

2,119

1,863

Other comprehensive income (loss):
Unrealized gain on available-for-sale securities, net of tax

0

-

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain (loss) on investment securities

-

-

-

-

-

-

-

-

0

-

-62

-102

66

319

282

300

-56

-302

-204

-204

0

-

0

0

-

Net Income (Loss) Attributable to Parent

-70,373

-112,477

-110,716

-102,485

-99,724

-98,036

-92,734

-92,364

-92,646

-91,779

-89,799

-84,087

-76,139

-69,241

-66,151

-61,840

-55,865

-48,548

-105,998

-96,686

-89,433

-83,965

0

0

0

Other comprehensive loss:
Foreign currency translation adjustment

-269

-228

-41

-18

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-25,873

0

-

0

0

-

Comprehensive income (loss)

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

-

-

-

-

-

-